USE OF IVERMECTIN IN COVID-19

Ankita Jadhao^*, Pramita Muntode and Ashok Mendhale

^*Correspondence: Dr. Ankita Jadhao, Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Maharashtra, India, Email:

Author info »

Introduction

In December 2019, a wave of acute atypical respiratory illness patients was reported in Wuhan, China. This swiftly swept throughout China, starting in Wuhan. The new COVID-19 was termed as severe acute respiratory distress syndrome Coronavirus-2 (COVID-19) because to its strong resemblance (80%) to SARS-CoV-2, which gave rise to Acute Respiratory Distress Syndrome (ARDS) and significant fatality between 2002–2003 [1]. The SARSCoV- 2 wave is considered to have started with a zoonotic illness linked to a seafood market in Wuhan, China. Person to person transmission was later shown to have had a significant part in the outbreak that ensued [2]. The Coronavirus is a virus that typically affects the lungs, but it can potentially impact other organ systems. Coronavirus has a single-stranded positive sense RNA that is encased in an external membrane with a crown shaped array of spiked glycoproteins. Coronavirus infection can result in a wide range of symptoms and morbidity, depending on the patients, their genome, race, age and geographic region. Pulmonary epithelial cell death, thrombosis, hyper coagulation and vascular leak are all part of COVID-19 pathophysiology, which can lead to sepsis in severe instances. As a result of these events, ARDS and lung fibrosis occur. Pyrexia, dry cough and dyspnea were among the manifestation of lower airway infection in the first wave series from Wuhan, China [3]. There is no particular treatment available at this time and medical management is primarily supportive. Drug trials have looked at lopinavir ritonavir, remdesivir, hydroxylchloroquine and azithromycin, among other medicines [4-6].

Coronavirus disease (COVID-19) has risen as a global outbreak of crucial priority, driven by the novel severe acute respiratory disorder Coronavirus 2 [7]. 81% of cases are classed as light, in which case home based symptom management and clinical deterioration monitoring are recommended. Despite the availability of symptomatic therapy, a therapeutic drug that can delay infection progression is urgently needed.

Literature Review

Mechanism of Coronavirus disease-19

Quick multiplication of Coronavirus promotes amplification of the immunity, which can result to a cytokine storm, which typically leads in a severe lung inflammation in response to it [8]. As the illness advances, alveolar damage can lead to increased respiratory failure and, eventually, death [9]. Furthermore, assessing the viral load of Coronavirus in the upper airway and Bronchoalveolar Lavage Fluid (BALF) in cases with severe infection reveals elevated loads and longer viral persistence [9-12].

Invasion in host cells

COVID-19 viruses are positive sense single stranded RNA viruses with a single stranded RNA and a 30 kb contained genome. They may infect contaminate of diversity of animals [13]. They are commonly classified into 4 group based on their genetic structure: α-alpha, β-beta, gamma and delta. The α-alpha and βeta Coronaviruses only infect animals [14]. COVID viruses that result in cold and croup are known as human COVID-19 viruses, such as 229E and NL63. Coronaviruses, on the other hand, include the SARS-CoV-2, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV-2) and the COVID-19 is classified to β Coronaviruses. The 5 phases in the Corona virus's life cycle with the patient’s cells are attachment, penetration, biosynthesis, maturity and release. After connecting to host cell receptors (attachment), Corona viruses penetrate host cells through endocytosis. COVID-19 has 4 structural proteins: Spike (S), Membrane (M), Envelop (E) and Nucleocapsid (N) [15].

Host response to COVID-19

COVID-19 infection causes symptoms that extent from moderate respiratory distress to serious respiratory syndrome with several organs failure [16]. Coronavirus have been shown to penetrate host cells by receptor mediated endocytosis [17], which happens when the virus's receptor binding domain binds to the homologous receptor on the host cell.

Because the lungs are the first part of body to cause infection with COVID-19 [18,19], it's critical to understand how the virus penetrates the lower airway and which cellular target in the lungs are susceptible to infection. The majority of COVID-19 infected droplets produced by the patient are in the optimal range (1–10 m) for reaching the deeper parts of the lung. Alveolar type 2 epithelial cells indicated the most angiotensin converting receptor-2 relative to other pulmonary cell types, according to a single cell transcriptome analysis of healthy pulmonary tissue samples taken from a range of individuals [20]. Despite modest levels of angiotensin converting receptor-2 production in majority pulmonary tissue, increased angiotensin converting receptor-2 production in alveolar type 2 cells may allow COVID to infect pulmonary tissue. In addition, alveolar type 2 cells function as hosts for the COVID-19 virus and generate greater levels of inflammatory cytokines [21]. Viral envelope proteins get attached to and degrade angiotensin converting receptors-2 receptors, inhibiting normal angiotensin converting receptors 2 function. Coronavirus infection results in ACE-2 abnormalities as well as an inflammation immunological reaction known as a cytokine disturbance, all of which aggravates the patient’s comorbidity.

Transmission

The most prevalent form of transmission is now universally recognized as human to human transmission. People who are asymptomatic can potentially spread the infection to others. The most prevalent source of infection, on the other hand, is symptomatic individuals. Transmission occurs when respiratory droplets are disseminated by coughing or sneezing. According to the findings, close contact between persons might result in transmission. This also shows that increasing aerosol concentrations in confined areas might induce transmission [22].

Clinical features

In individuals with a mild illness, manifestation of an upper respiratory passage disease may be evident. A dry cough, a slight pyrexia, nasal blockage, pharyngitis, headache, muscle tenderness and malaise are some of the symptoms. The lack of severe, manifestation such as difficulty in breathing can also be used to diagnose it. In those with moderate disease, cough, difficulty in breathing and tachypnea are frequent respiratory symptoms [22].

Severe pneumonia, ARDS, sepsis and septic shock are all symptoms of a severe illness. Within 24 to 48 hours, patients may experience severe breathlessness, tachypnea (respiratory rate >30/minute), difficulty breathing, SpO₂ 93 percent, PaO₂/FiO₂ 300 and/or more than 50% lung infection. Fever may be absent or moderate even in the major severe infection of the disease [22].

Ivermectin

This drug is a broad spectrum antibiotic that has been used as anti-parasitic in humans for more than 30 years [23]. In vitro, ivermectin has been shown to exhibit antiviral effect against the Zika virus, Influenza A virus, Newcastle disease virus, Chikungunya virus, Yellow fever virus, Dengue virus, Japanese encephalitis virus, BK polyomavirus and Equine herpesvirus type 1 [24]. Because it is produced by the soil bacteria streptomyces avermitilis, ivermectin is also known as an ivermectins [25].

Mechanism of ivermectin

The anti-parasitic medication ivermectin inhibits coronavirus by inhibiting viral proteins from penetrating the nucleus of the host cell [26]. In a simulated pharmacological screening, doxycycline was recently discovered as a putative suppressive of COVID-19 papain-like protease [27]. Ivermectin is a macro cyclic lactone molecule with 16 members that belongs to the avermectin family [28]. Higher doses and more consistent regimens of ivermectin are regarded to be safe. Higher dosages of ivermectin, such as 120 mg (up to 2,000 g/kilogram) given once or 180 mg (up to 3,000 g/ kilogram) given in divided regimen about a 7 days, were well tolerated and safe [29]. It has also demonstrated antiviral effect against a range of RNA and DNA viruses and it is now being tested in Coronavirus [30].

Ivermectin, a broad spectrum antibiotic with high lipid solubility, has been discovered to have a variety of impacts on parasites, nematodes, arthropods, Flavivirus, mycobacteria and mammals via different pathways. This drug is anti-parasitic and antiviral, but it also has an effect on the immunological system of the host. Studies have shown that it can reduce cancer cell growth in addition to controlling glucose and cholesterol in animals. It can also be used in cases when hydroxychloroquine isn't available. In some cases, hydroxychloroquine is restricted in COVID-19 because of the danger of QTC prolongation and the fact that potential antiviral tissue levels take 5-10 days to develop at the highest regular dose [31].

Ivermectin hasn't been connected to any of these negative effects and it's also a less expensive choice [32]. The antiviral mechanism of ivermectin is assumed to be in relation to its regulation of virus and host nuclear protein import. Ivermectin reduces IMP/1 import while enhancing the antiviral response, which is required by the majority of RNA viruses at the time of infection [33]. Ivermectin binds to the import in α (armadillo repeat) state in this process, resulting in thermally stable and a structural alteration in α-helicity that inhibits attachment to import in β-1 [34,35]. Ivermectin's anti-SARS-CoV-2 activity is most likely due to reduction of viral IMP/1 mediated nuclear import, which decreases virus replication and therefore viral burden. [36]. Ivermectin has also been proposed to function as an ionophore [37].

Ivermectin might induce an ionic imbalance that affects the viral membrane's potential, putting its integrity and functionality at risk [38]. As ionosphere substances have been characterized as possible antiviral treatments. Another method of action for ivermectin is considered to be the Trans membrane receptor CD 147. CD 147 has been considered as a key COVID-19 spike protein binding site, along with ACE-2. To examine the possibility for substantial dose response increases, studies suggesting that ivermectin protect COVID-19 spiked protein that gets attached to CD 147 and angiotensin converting enzyme-2 [39] are employed. Another mechanism of action to examine is ivermectin's allosteric modulation of the P₂X₄ receptor.

Discussion

According to Dayer ivermectin is one of the most effective medications for preventing COVID spiked protein from interacting with host cell receptors [40]. According to a research done by Daghir Janabi [41], ivermectin has a high binding affinity for RNA dependent RNA polymerase.

Ivermectin's antiviral effectiveness against coronavirus, the COVID-19 causal agent, was described by Caly, et al. [42]. After a single dose of ivermectin, the growth of an Australian strain of COVID-19 in Vero/HSLAM cells was decreased by 5000 fold. Physicians, academics and health professionals from all over the world have been intrigued by this discovery. However, these data should be treated with care. To begin, the medication was only evaluated on a monkey kidney cells in vitro and that was genetically modified to generate human Signaling Lymphocytic Activation Molecule (SLAM), also known as CDW 150 [42]. In addition, ivermectin was stated to lower viral RNA by 5000 times in 48 hours and that the IC50 was determined to be 2 μM. This research was the first to look into the activity of ivermectin against coronavirus. According to the researchers, the medicine may have therapeutic potential by suppressing the importin (IMP)/ receptor, which transfers viral proteins in nucleus of the host cell. According to the researchers, human trials are required to confirm the potential advantages of ivermectin in the management of COVID-19. Despite the fact that this was the first trial to indicate that ivermectin is antiviral on COVID-19 [42]. It was shown to be ineffective.

Rajter, et al. studied Coronavirus infected patients hospitalized to a South Florida hospital in a retrospective cohort analysis (n=280). They compared 173 patients who undergone ivermectin treatment (at the minimum one dose of 200 mcg/kilogram via oral route along with usual clinical care) to 107 patients who undergone standard management, discovered that ivermectin management was associated with low death rate, especially in who needed more oxygen or ventilator support [43].

We discovered five researches of ivermectin in Coronavirus infection at European Union clinical studies register (2020-001994-66, 2020-001971-33, 2020-002091-12, 2020-001474-29, 2020-002283-32) [44]. Ivermectin is now being examined in at least five studies in India, according to the official website Clinical Studies Registry India (CTRI) [45]. The US clinical research database currently lists 38 research trials in varying stages of the work from several countries. Ivermectin has been used in clinical studies at dosages range from 200 to 1200 micrograms per kilogram of body weight for 3–7 days, with excellent effects in terms of viral load and symptomatology. Two in vivo studies have been conducted on ivermectin as single or in combined with doxycycline.

The authors discovered that the ivermectin and doxycycline combine had a higher favorable rate of indicative relief, a shorter recovery time, fewer side effects and better compliance than the hydroxychloroquine azithromycin combination therapy when 116 patients undergone treatment with ivermectin combined with doxycycline (no=60), hydroxychloroquine combined with azithromycin (no=56). For those with mild to moderate COVID-19 illness, ivermectin was found to be a superior option. In a retrospective analysis of 280 patients with COVID-19 disease undergone treatment with ivermectin (n=173) or standard management (n=107) and a total of 280 patients with Coronavirus infection undergone treatment with ivermectin (n=173) or standard management (n=107) the authors discovered that the ivermectin group had a decreased death rate (25.2 percent vs 15.0 percent, OR 0.52, 95 percent CI 0.29). Patients with severe lung illness (n=75) were managed with ivermectin had a low death rate (38 percent, vs. 80.7%). The researchers also discovered a substantial change in successful extubation rates.

Conclusion

Coronavirus epidemic is sweeping the world in danger. It has resulted in more infections and fatalities than either SARS or Ebola. COVID-19, unlike SARS or MERS, is considered to be more infectious. The elderly and immune compromised people are the one who are at risk. The main principle of Coronavirus outbreak is to stop the virus from increasing and to develop therapeutic treatments that improve cure rates while decreasing total mortality. To obtain this aim, an absolute recognition of all aspects of COVID virus is essential in order to avoid or limit potential civilization wide impact.

Ivermectin is an anti-parasitic drug that also works as a broad spectrum antibacterial agent to treat viral infections.

According to early findings, ivermectin, an import in/1/ mediated nuclear import inhibitor, suppressed COVID-19 in vitro. Many studies have recognized the involvement of ivermectin in Coronavirus disease. Since a result of these findings, ivermectin might be a probable therapy of choice for Coronavirus infected patients, as it reduced mortality and improved symptoms, according to clinical investigations. Ivermectin is safe in SARS-CoV-2 patients and lowers symptomatology as well as the virus's viral load.

Furthermore, ivermectin in combination with doxycycline looks to be effective. ivermectin's molecular selectivity is highly diverse, as evidenced by its excellent binding properties with both S1 and S2 domains, as well as a CL protease inhibitor site.

A five-day ivermectin regimen ensured in quicker virus clearance when compared to placebo, thus specify that advance treatment with this medicine may minimize virus proliferation in the patients. By 7th day, CRP and LDH, which are indicators of sickness severity, were considerably decreased in the five-day ivermectin group. In the lack of other diseases, a five days regimen of ivermectin therapy resulted in quicker SARS-CoV-2 virus clearance. Ivermectin may have a crucial level of care in a variety of biological processes as a result of its antiviral effect, making it a good option, COVID-19 is one of the viruses that can be treated with this drug. More study is needed for prospective human benefits in current and future pandemics because clinical, In order to assess the result of ivermectin on Coronavirus in a clinical context, more research is required. The FDA put out a statement on April 10, 2020, about administering to oneself of ivermectin in COVID infected patients. Citing a freshly reported in vitro analysis. This form of in vitro study is most commonly utilized in the recent phase of pharmaceutical evolution, according to the FDA. Furthermore, additional study is required to show the effectiveness and ivermectin's anti-Coronavirus safety in humans in order to develop a preventive or therapeutic window.

References

1. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-1966.

   [Crossref][Googlescholar][Indexed]

2. Li X, Guan P, Wu X, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus infected pneumonia. N Engl J Med 2020; 382:1199-1207.

   [Crossref][Googlescholar][Indexed]

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet 2020; 395:497-506.

   [Crossref][Googlescholar][Indexed]

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395:1054-1062.

   [Crossref][Googlescholar][Indexed]

5. Cao B, Wang Y, Wen D et al. A trial of lopinavir ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020; 382:1787-1799.

   [Crossref][Googlescholar][Indexed]

6. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open label non-randomized clinical trial revisited. Int J Antimicrob Agents 2021; 57:106243.

   [Crossref][Googlescholar][Indexed]

7. Ahmed S, Karim MM, Ross AG, et al. A five days course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis 2021; 103:214-216.

   [Crossref][Googlescholar][Indexed]

8. Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J Clin Invest 2020; 130:2202-2205.

   [Crossref][Googlescholar][Indexed]

9.  
10. Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new Coronavirus of probable bat origin. Nature 2020; 579:270-273.

    [Crossref][Googlescholar][Indexed] 

11. Wolfel R, Corman M, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465-469. 

    [Crossref][Googlescholar][Indexed]

12. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382:1177-1179. 

    [Crossref][Googlescholar][Indexed]

13. Zheng S, Fan J, Yu F et al. Liang viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-march 2020: Retrospective cohort study. BMJ 2020; 369:m1443. 

    [Crossref][Googlescholar][Indexed]

14. Channappanavar R, Zhao J, Perlman S. T cell mediated immune response to respiratory Coronaviruses. Immunol Res 2014; 59:118-128.

    [Crossref][Googlescholar][Indexed]

15. Rabi FA, Al Zoubi MS, Kasasbeh GA, et al. SARS-CoV-2 and Coronavirus Disease 2019: What we know so far. Pathogens 2020; 9:231.

    [Crossref][Googlescholar][Indexed]

16. Bosch BJ, van der Zee R, de Haan CA, et al. The Coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. J Virol 2003; 77:8801-8811.

    [Crossref][Googlescholar][Indexed]

17. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-1720.

    [Crossref][Googlescholar][Indexed]

18. Grove J, Marsh M. The cell biology of receptor mediated virus entry. J Cell Biol 2011; 195:1071-1082.

    [Crossref][Googlescholar][Indexed]

19. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms. Lancet Respir Med 2020; 8:750-752.

    [Crossref][Googlescholar][Indexed]

20. Hou YJ, Okuda K, Edwards CE, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 2020; 182:429-446.

    [Crossref][Googlescholar][Indexed]

21. Madissoon E, Wilbrey Clark A, Miragaia RJ, et al. SCRNA-seq assessment of the human lung, spleen and esophagus tissue stability after cold preservation. Genome Biol 2019; 21:1.

    [Crossref][Googlescholar][Indexed]

22. Xu J, Xu X, Jiang L, et al. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res 2020; 21:182.

    [Crossref][Googlescholar][Indexed]

23. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation and treatment of Coronavirus (COVID-19). Stat Pearls 2020.

    [Googlescholar][Indexed]

24. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008; 31:91-98.

    [Crossref][Googlescholar][Indexed]

25. Gupta D, Sahoo AK, Singh A. Ivermectin: Potential candidate for the treatment of COVID-19. Braz J Infect Dis 2020; 24:369-371.

    [Crossref][Googlescholar][Indexed]

26. Campbell WC, Benz GW. Ivermectin: A review of efficacy and safety. J Vet Pharmacol Ther 1984; 7:1-16.

    [Crossref][Googlescholar][Indexed]

27. Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10:766-788.

    [Crossref][Googlescholar][Indexed]

28. Juarez M, Schcolnik Cabrera A, Duenas Gonzalez A. The multitargeted drug ivermectin: From an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res 2018; 8:317-331.

    [Googlescholar][Indexed]

29. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002; 42:1122-1133.

    [Crossref][Googlescholar][Indexed]

30. Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 2020; 73:593-602.

    [Crossref][Googlescholar][Indexed]

31. Scheim D. Ivermectin for COVID-19 treatment: Clinical response at quasi-threshold doses via hypothesized alleviation of CD147 mediated vascular occlusion. SSRN J 2020.

    [Googlescholar]

32. Gupta D, Sahoo AK, Singh A. Ivermectin: Potential candidate for the treatment of COVID-19. Braz J Infect Dis 2020; 24:369-371.

    [Crossref][Googlescholar][Indexed]

33. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: Trends, scope and relevance. New Microbes New Infect 2020; 35:100684.

    [Crossref][Googlescholar][Indexed]

34. Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of import in α/β mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 2012; 443:851-856.

    [Crossref][Googlescholar][Indexed]

35. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce venezuelan equine encephalitis virus replication. Antiviral Res 2013; 100:662-672.

    [Crossref][Googlescholar][Indexed]

36. Rizzo E. Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol 2020; 393:1153-1156.

    [Crossref][Googlescholar][Indexed]

37. Sandler ZJ, Firpo MR, Omoba OS, et al. Novel ionophores active against La Crosse virus identified through rapid antiviral screening. Antimicrob Agents Chemother 2020; 64:e00086-20.

    [Crossref][Googlescholar][Indexed]

38. Dayer MR. Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatics study. Preprints 2020.

    [Googlescholar][Indexed]

39. Daghir Janabi AH. Effective Anti-SARS-CoV-2 RNA dependent RNA polymerase drugs based on docking methods: The case of milbemycin, ivermectin and baloxavir marboxil. Avicenna J Med Biotechnol 2020; 12:246-250.

    [Googlescholar][Indexed]

40. Caly L, Druce JD, Catton MG, et al. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178:104787.

    [Crossref][Googlescholar][Indexed]

41. Rajter JC, Sherman MS, Fatteh N, et al. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in COVID nineteen study. Chest 2021; 159:85-92.

    [Crossref][Googlescholar][Indexed]

42. EU Clinical Trials Register. Clinical trials for ivermectin and COVID-19. 2021.
43. A novel Coronavirus associated with severe acute respiratory syndrome
44. ClinicalTrials.gov. COVID-19 ivermectin. U.S. Department of Health and Human Services. 2020.
45. Taiub A, Chowdhury MM, Shahbaz M, et al. A randomized trial of ivermectin doxycycline and hydroxychloroquine azithromycin therapy on COVID-19 patients. Research Square 2020.

    [Googlescholar]

46. FDA. FDA letter to stakeholders: Do not use ivermectin intended for animals as treatment for COVID-19 in humans. 2020